Kodiak Sciences showcases KSI-101, a potential new treatment for macular edema, at the 2025 IOIS Congress, aiming to better ...

The trial is evaluating KB803 for the treatment and prevention of corneal abrasions in dystrophic epidermolysis bullosa ...

Qlaris Bio to showcase promising data on QLS-111, a novel glaucoma treatment, at the 2025 World Glaucoma Congress, ...

ADX-2191 is an investigational drug candidate from Aldeyra, for the treatment of primary vitreoretinal lymphoma (PVRL), a ...

New findings reveal RG6501 cell therapy shows promising long-term visual improvements for geographic atrophy patients ...

FYB203 has been approved by the US FDA and UK Medicines and Healthcare products Regulatory Agency for the treatment ...

ST-100 shows promise as a fast-acting treatment for dry eye disease, offering rapid relief and unique collagen repair ...

ForSight Robotics secures $125M to advance its robotic surgery platform, targeting cataract procedures and additional ...

Danegaptide is an oral therapy for early treatment of non-proliferative diabetic retinopathy (NPDR) and associated edema.

The ophthalmic drug development industry is undergoing significant transformation, marked by unprecedented advancements in ...

As its director, Manusis outlines the facility’s role in delivering advanced, personalized solutions to improve vision and ...

Kira Manusis, MD, is Director of the Center for Refractive Solutions and Co-Director of Cataract Services at NYEE.